Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults
BERKELEY, CA -- (Marketwired) -- November 9, 2017 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Hepatitis | Hepatitis B | Hepatitis Vaccine | Vaccines